Epilepsy

As per the WHO, roughly 50 million people worldwide have Epilepsy. The burden of Epilepsy is growing in almost every geographic region. According to the Global Burden of Disease report on the burden of neurological diseases, it is observed that idiopathic epilepsy accounted for 5% of all neurological DALYs and 1.3%...

Epidiolex (Jazz Pharma) and Fintepla (Zogenix - Acquired by UCB) are locking horns in the rare developmental and epileptic encephalopathies (DEE) market with Epidiolex currently leading in terms of sale. Epidiolex has clocked over USD 650 million in sales and on the other hand Fintepla is far behind at just USD 74....

Check-Cap Initiated the US Pivotal Trial for C-Scan® On May 11, 2022, Check-Cap Ltd., a clinical-stage diagnostic company initiated the US pivotal trial for C-Scan® at Mayo Clinic in Rochester Minnesota. C-Scan is the first and only patient-friendly, preparation-free screening test to detect polyps before they m...

Sanofi’s Rare Disease Drug Xenpozyme Wins World’s First Approval in Japan Sanofi’s Xenpozyme, also known as olipudase alfa, the world's first therapy for the rare disease Niemann-Pick type A/B and B, has been approved for the treatment of children and adults with non-CNS manifestations of Acid Sphingomyelinase D...

Cannabidiol (CBD) is one of the 120 cannabinoids present naturally in cannabis plants. After tetrahydrocannabinol (THC), Cannabidiol is the second most prevalently available cannabinoid. Cannabidiol, an important component of medicinal marijuana, is either directly from the hemp plant or synthesized in a laboratory...

Deep brain stimulation (DBS) is a surgical procedure that requires the implantation of a device capable of sending electrical impulses to the brain areas responsible for body movement. A DBS system is composed of the neuro-stimulator, leads, and extension. The electrodes are placed deep inside the brain and are lin...

Which Pharma Companies are Transforming the Drug-Resistant Epilepsy Market Landscape? In the United States, more than 2.5 million people are living with Epilepsy, out of which approximately 1 million continue to experience seizures despite adequate treatment with antiseizure drugs. Known as Drug-resistant epilep...

The term Epilepsy isn’t new. It’s been present in the air for centuries now, however, only a few are aware that it is one of the most common neurological diseases in the world. It affects around 50 million people worldwide. However, public awareness regarding Epilepsy is quite less and it can result in the ris...

Potential and growth of the current market The major drawback of the current antiepileptic drugs (AEDs) is their modest efficacy even at best; therefore, many patients require as many as four concurrent AEDs and contend with their host of side effects. The epilepsy market has witnessed several approvals in the l...

50 million people globally have dementia, and out of all the dementia cases, Alzheimer’s Disease accounts for about 60–70% of cases, says the WHO. Alzheimer's Disease is a neurodegenerative disease, a common cause of dementia that affects behavior, memory, and thinking abilities of an individual. Mostly the symptom...